Complement activation in patients with focal segmental glomerulosclerosis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Thurman, Joshua M ^a   Wong, Maria ^a   Renner, Brandon ^a   Frazer Abel, Ashley ^b   Giclas, Patricia C ^b   Joy, Melanie S ^a   Jalal, Diana ^a   Radeva, Milena K ^c   Gassman, Jennifer ^c   Gipson, Debbie S ^d   Kaskel, Frederick ^e   Friedman, Aaron ^f   Trachtman, Howard ^g  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT BA; COMPLEMENT COMPONENT BB; COMPLEMENT COMPONENT C4A; COMPLEMENT MEMBRANE ATTACK COMPLEX; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C5B;

ADULT; ARTICLE; BLOOD ANALYSIS; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; SCHOOL CHILD; URINALYSIS; VASCULITIS; ADOLESCENT; BLOOD; METABOLISM; URINE;

ADOLESCENT; ADULT; CHILD; COMPLEMENT ACTIVATION; COMPLEMENT C5B; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE;

EID: 84947460124     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136558     Document Type: Article

References (36)

1. Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chron Kidney Dis. 2011; 18:332-338.
2. Sadowski CE, Lovric S, Ashraf S, Pabst WL, Gee HY, Kohl S, et al. A Single-Gene Cause in 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome. J Am Soc Nephrol. 2014; 26:1279-1289. doi: 10.1681/ASN.2014050489 PMID: 25349199
3. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17:952-960. doi: 10.1038/nm.2411 PMID: 21804539
4. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5:2115-2121. doi: 10.2215/CJN.03800609 PMID: 20966123
5. Gephardt GN, Tubbs RR, Popowniak KL, McMahon JT. Focal and segmental glomerulosclerosis. Immunohistologic study of 20 renal biopsy specimens. Arch Pathol Lab Med. 1986; 110:902-905. PMID: 2429634
6. Habib R, Girardin E, Gagnadoux MF, Hinglais N, Levy M, Broyer M. Immunopathological findings in idiopathic nephrosis: clinical significance of glomerular "immune deposits". Pediatr Nephrol. 1988; 2:402-408. PMID: 3153051
7. Newman WJ, Tisher CC, McCoy RC, Gunnells JC, Krueger RP, Clapp JR, et al. Focal glomerular sclerosis: contrasting clinical patterns in children and adults. Medicine. 1976; 55:67-87. PMID: 1107746
8. Lenderink AM, Liegel K, Ljubanovic D, Coleman KE, Gilkeson GS, Holers VM, et al. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. American journal of physiology. Renal physiology. 2007; 293:F555-564. PMID: 17522263
9. Turnberg D, Lewis M, Moss J, Xu Y, Botto M, Cook HT. Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice. J Immunol. 2006; 177:4094-4102. PMID: 16951374
10. Strassheim D, Renner B, Panzer S, Fuquay R, Kulik L, Ljubanović D, et al. IgM Contributes to Glomerular Injury in FSGS. J Am Soc Nephrol. 2013; 24:393-406. doi: 10.1681/ASN.2012020187 PMID: 23393315
11. Daha MR, Fearon DT, Austen KF. C3 requirements for formation of alternative pathway C5 convertase. J Immunol. 1976; 117:630-634. PMID: 950465
12. Walport MJ. Complement. First of two parts. N Engl J Med. 2001; 344:1058-1066. PMID: 11287977
13. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, et al. Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic Syndrome. Clin J Am Soc Nephrol. 2009; 4:1920-1924. doi: 10.2215/CJN.02730409 PMID: 19820137
14. Scholl HP, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B, Börncke F, et al. Systemic complement activation in age-related macular degeneration. PloS one. 2008; 3(7):e2593. doi: 10.1371/journal.pone.0002593 PMID: 18596911
15. Daina E, Noris M, Remuzzi G. Eculizumab in a patient with dense-deposit disease. N Engl J Med. 2012; 366:1161-1163. doi: 10.1056/NEJMc1112273 PMID: 22435382
16. Morita Y, Ikeguchi H, Nakamura J, Hotta N, Yuzawa Y, Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol. 2000; 11:700-707. PMID: 10752529
17. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol. 1999; 10:2323-2331. PMID: 10541291
18. Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011; 80:868-878. doi: 10.1038/ki.2011.195 PMID: 21734640
19. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, et al. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int. 2011; 79:678-685. doi: 10.1038/ki.2010.485 PMID: 21178977
20. Mollnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clinical and experimental immunology. 1988; 73:484-488. PMID: 2463123
21. Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2013; 83:129-137. doi: 10.1038/ki.2012.313 PMID: 22913983
22. Perrin LH, Lambert PH, Miescher PA. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest. 1975; 56:165-176. PMID: 1141431
23. Chua JS, Baelde HJ, Zandbergen M, Wilhelmus S, van Es LA, de Fijter JW, et al. Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy. J Am Soc Nephrol. 2015 Jan 8. pii: ASN.2014050429.
24. Sun Q, Jiang S, Li X, Xie K, Cheng D, Chen J, et al. The prevalence of immunologic injury in renal allograft recipients with de novo proteinuria. PLoS One. 2012; 7(5):e36654. doi: 10.1371/journal.pone.0036654 PMID: 22586485
25. Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int. 1991; 39:811-821. PMID: 1829775
26. Cosio FG, Hernandez RA. Favorable prognostic significance of raised serum C3 concentration in patients with idiopathic focal glomerulosclerosis. Clin Nephrol. 1996; 45:146-152. PMID: 8706354
27. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004; 43:368-382. PMID: 14750104
28. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004; 15:2169-2177. PMID: 15284302
29. Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol. 2012; 23:1769-1776. doi: 10.1681/ASN.2012040389 PMID: 22997260
30. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013; 84:1079-1089. doi: 10.1038/ki.2013.377 PMID: 24172683
31. Salinas-Carmona MC, Perez LI, Galan K, Vazquez AV. Immunosuppressive drugs have different effect on B lymphocyte subsets and IgM antibody production in immunized BALB/c mice. Autoimmunity. 2009; 42:537-544. doi: 10.1080/08916930903019119 PMID: 19657777
32. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem. 1999; 45:1190-1199. PMID: 10430784
33. Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, et al. Cyclosporine induces endothelial cells to release complement-activating microparticles J Am Soc Nephrol. 2013: 24:1849-1862.
34. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012; 23:2051-2059. doi: 10.1681/ASN.2012030302 PMID: 23138488
35. Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009; 4:1317-1323. doi: 10.2215/CJN.00570109 PMID: 19578004
36. Sethna C, Benchimol C, Hotchkiss H, Frank R, Infante L, Vento S, et al. Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant. 2011; 2011:389542. doi: 10.1155/2011/389542 PMID: 21577271